NasdaqGS:VRTXBiotechs
Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal Plans
Vertex Pharmaceuticals stock has delivered a 141.5% return over the past 5 years, and the latest intrinsic value work using a Discounted Cash Flow (DCF) approach now points to the shares trading at a discount to that estimate, even as the broader valuation checks look more mixed. With the market pricing in both the planned Crinetics Pharmaceuticals acquisition and ongoing revenue from existing partnerships, investors are weighing whether the current price still leaves enough cushion.
A...